A new investigational toothpaste, INT301, developed by New York-based biotech firm Intrommune, shows promise in treating adults with peanut allergies. The toothpaste, which exposes the body to increasingly tiny amounts of peanut protein, met its safety goals in a 4-month trial involving 32 adults. All participants tolerated the highest dose, with only mild itching reported as a reaction. Further trials will explore the toothpaste’s effectiveness in helping to desensitize adults to peanut protein.
Critical Claude Code Flaw Silently Bypasses Developer-Configured Security Rules
A high-severity security bypass vulnerability in Anthropic’s Claude Code AI coding agent allows malicious actors to silently evade user-configured deny rules through a simple command-padding
